- Q2 report Tuesday, 18 April at 08:30 CET - '25e-'27e adj.
Redeye positively views yesterday’s press release from Acarix announcing that it has secured its fir...
Coor förväntas redovisa en något lägre omsättning, men förbättrade marginaler tack vare lägre person...
Redeye comments on Litium’s Q2 report, returning to a solid ARR growth of 12%.
- Q2 report due Monday, 14 July - Adj. EBITA by 6-5% on '25e-'27e; 5% CAGR '24-'27e - Trading at 12-...
- SEK 72m follow-up order (Terminals) from Swedish FMV - Deliveries start in Q3 - Could add ~10% to ...
Active Biotech har tagit ett steg närmre ett partnerskap i och med slutförandet av LION-studien.
The company sells its Marine and Offshore Unit for EUR 7.
Redeye comments on Carasent’s preliminary Q2 figures, the revised 2025 targets, and the new mid-term...
Redeye comments on Isofol’s recently announced rights issue outcome.
According to the press release yesterday, the Board of Directors and Julian Read came to the mutual ...
Redeye makes several positive remarks following GomSpace's recent newsflow, which included a SEK215m...
- NOI +63% y-o-y and -4% vs ABGSCe - Rec PTP -1% vs ABGSCe, EC IFPM +1.
Hyresintäkterna steg med 62% till 15,2 meur och förvaltningsresultat ökade med över 50% till 7,9 meu...
- Expect continued order recovery but flat sales y-o-y - M&A resumed, 1.
- Sales to improve q-o-q, but still down y-o-y, growth in H2e - Raise '25e-'27e adj.
Duell’s first nine months of the fiscal year were negatively impacted by adverse weather and overall...
Redeye comments on the SEK29.4m rights issue of units and the restructuring initiatives by reducing ...
3.5m EEs, sales -13% (-8% FX), EBIT margin 36.2% (+5.
Rec. PTP -7% vs ABGSCe Vacancies up slightly, property value down -0.
